13.2 VTE in the Neuro ICU (01.T.5)
Key Takeaways
- Start intermittent pneumatic compression on admission in nonambulatory ICH, TBI, SAH, and postoperative patients unless a limb contraindication exists; graduated compression stockings alone are not VTE prophylaxis.
- Pharmacologic prophylaxis after ICH, TBI, or craniotomy is often begun in a 24–72 hour window if imaging is stable, but the evidence is limited, class of recommendation is modest, and no universal hour is proven.
- AHA/ASA 2022 states that low-dose UFH or LMWH beginning 24–48 hours after ICH onset may be reasonable (Class 2b) and that IPC from the day of diagnosis is Class 1.
- When therapeutic anticoagulation is absolutely contraindicated after proximal DVT, a retrievable IVC filter can bridge; retrieve it when anticoagulation becomes possible. Filters are not add-on therapy on top of anticoagulation (PREPIC2).
- HIT is a falling platelet count plus thrombosis 5–10 days after heparin (sooner if recent exposure): stop all heparin, start a non-heparin anticoagulant such as argatroban, and do not start warfarin until the count recovers.
A dense hemiparesis, an EVD, a craniotomy dressing, and a week of bed rest are a venous thrombosis machine. Pulmonary embolism (PE) then competes with hematoma expansion for the title of preventable death. This independent OpenExamPrep section covers venous thromboembolism (VTE) prophylaxis and treatment in the neuro ICU as listed in the ABPN Content Specifications. It is not an ABIM or ABPN product. The examination reward is knowing what starts immediately, what waits on a stable scan, and what to do when PE and intracranial bleeding occupy the same patient.
Mechanical prophylaxis starts now
Intermittent pneumatic compression (IPC) belongs on the calves (or thighs, device-dependent) as soon as the patient is nonambulatory, unless a limb is ischemic, has an untreated acute DVT already being managed, or has a wound that the sleeve would destroy. The CLOTS 3 trial in acute stroke showed that IPC reduced proximal deep-vein thrombosis (DVT). The CLOTS 1 trial showed that graduated compression stockings did not prevent DVT after stroke and caused skin injury. The 2022 American Heart Association/American Stroke Association (AHA/ASA) ICH guideline therefore gives IPC starting on the day of ICH diagnosis a Class 1 recommendation in nonambulatory patients, and it gives stockings alone a Class 3 (no benefit) recommendation. TBI, SAH, and craniotomy patients get the same mechanical logic even when the Class 1 citation is written for ICH: the clot risk begins on hour one, and heparin is not yet on board.
IPC compliance is the hidden failure mode. Sleeves on the floor, sleeves off for a trip to CT, and sleeves omitted on a crushed leg all count as “no prophylaxis.” Document why a limb is uncovered and cover the other limb.
Pharmacologic timing: a window, not a universal hour
Low-dose unfractionated heparin (UFH) (commonly 5,000 units subcutaneously every 8–12 hours) or low-molecular-weight heparin (LMWH) (commonly enoxaparin 40 mg daily, adjusted for renal failure and extreme weight) reduces PE. After a brain bleed or a fresh craniotomy, that benefit is purchased with a theoretical risk of hematoma growth. Randomized evidence that pins a single safe hour is thin. Practice and modest-grade guidelines therefore speak in windows, contingent on hematoma stability on repeat imaging, not on a fake universal stopwatch.
For spontaneous ICH, AHA/ASA 2022 says low-dose UFH or LMWH can be useful to reduce PE (Class 2a) and that starting 24–48 hours from ICH onset may be reasonable to balance thrombosis prevention against hematoma expansion (Class 2b). That is not a command to dose heparin at hour 24 in every patient. An expanding hematoma, an uncorrected coagulopathy, or an untreated aneurysm is a reason to wait. A stable repeat CT, controlled blood pressure, and completed reversal are reasons to start inside that window rather than waiting a week.
For TBI and after craniotomy, many protocols start prophylactic heparin or LMWH 24–72 hours after injury or surgery if a repeat CT shows a stable hematoma. Neurocritical Care Society VTE guidance has suggested initiating prophylaxis by 24–48 hours when hemorrhage is not expanding, but centers still vary, and the supporting trials are not large randomized comparisons of hour 24 versus hour 72. Say that on the examination: evidence is limited and practice varies. Do not invent “always at 36 hours” or “never before day 7.” Coordinate with the neurosurgeon after craniotomy; an unexpected postoperative hematoma resets the clock.
After aneurysmal SAH, mechanical prophylaxis starts immediately. Pharmacologic prophylaxis is commonly deferred until the aneurysm is secured and then started within a day or two if there is no further bleeding — again a practice pattern, not a universal hour. After ischemic stroke without hemorrhage, pharmacologic prophylaxis can start once hemorrhage has been excluded, often the same day, because there is no hematoma to expand. After intravenous thrombolysis, many services wait 24 hours and a stable follow-up scan before heparin, mirroring post-lytic imaging practice.
LMWH is more effective than UFH for DVT prevention in several medical populations and is convenient once-daily. UFH is easier to stop and is preferred by some surgeons immediately after craniotomy and in fluctuating renal function. Neither is treatment-dose anticoagulation.
| Setting | Mechanical | Pharmacologic prophylaxis (typical practice) | Certainty |
|---|---|---|---|
| Nonambulatory ICH | IPC day of diagnosis | Low-dose UFH/LMWH often 24–48 h if hematoma stable (AHA/ASA 2022, Class 2b) | IPC: strong; drug timing: modest |
| TBI | IPC on arrival | Often 24–72 h if repeat CT stable | Limited RCT timing data |
| After craniotomy | IPC immediately | Often 24–72 h if no unexpected hematoma | Surgeon-dependent |
| SAH, unsecured aneurysm | IPC | Usually wait until secured | Practice pattern |
| Ischemic stroke, no bleed | IPC | Same day after hemorrhage excluded | Stronger medical-stroke evidence |
| Stockings alone | Not sufficient | Not a substitute | CLOTS 1 / AHA Class 3 |
When PE and ICH occupy the same patient
This is the conflict the examination writes as a stem. A patient day 3 after ICH develops hypoxia, tachycardia, and a CT pulmonary angiogram that shows a proximal PE — or a duplex that shows an iliofemoral DVT. Full-dose anticoagulation now risks hematoma expansion. Withholding anticoagulation now risks fatal PE. There is no randomized “correct hour” for therapeutic anticoagulation after ICH.
AHA/ASA 2022 offers two modest statements. In ICH with proximal DVT who are not yet candidates for anticoagulation, temporary use of a retrievable inferior vena cava (IVC) filter is reasonable as a bridge until anticoagulation can start (Class 2a). In ICH with proximal DVT or PE, delaying treatment-dose UFH or LMWH 1–2 weeks after ICH onset might be considered (Class 2b). That delay is not mandatory and is not safe if the PE is obstructive and the right ventricle is failing. Massive PE with shock after a fresh ICH is a multidisciplinary catastrophe: systemic thrombolysis is usually off the table, catheter-based thrombectomy may be considered in selected centers, and a filter does not treat the clot already in the pulmonary arteries. Document the competing risks, image the hematoma, and do not pretend a single protocol covers every combination of PE size and hematoma age.
IVC filters reduce PE in the short term in older trials (PREPIC) but increase subsequent DVT and cause strut fracture, migration, and IVC thrombosis when left in place. PREPIC2 found that adding a retrievable filter to anticoagulation in PE with a high recurrence-risk score did not reduce recurrent PE at 3 months. The examination use-case is therefore narrow: anticoagulation absolutely contraindicated, preferably a retrievable device, with an explicit retrieval plan when the contraindication lifts. Do not place a permanent filter “just in case” in a 40-year-old who will be anticoagulated next week.
Heparin-induced thrombocytopenia
HIT is an immune reaction to platelet factor 4 (PF4)–heparin complexes. IgG antibodies activate platelets, producing thrombocytopenia plus thrombosis (arterial or venous), not bleeding. Timing is classically day 5–10 of heparin. If the patient received heparin within the previous 30 days (some scores allow up to 100 days), the count can crash within 24 hours of re-exposure (rapid-onset HIT). A drop of more than 50% from the postoperative peak, even if the nadir is still above 50 × 10^9/L, is enough. Skin necrosis at injection sites and anaphylactoid reactions to heparin boluses are HIT until proven otherwise.
Score pretest probability with the 4Ts: magnitude of thrombocytopenia, timing, thrombosis or other sequelae, and the presence of another cause. Low probability (0–3) makes HIT unlikely. Intermediate (4–5) or high (6–8) scores warrant laboratory testing and, if clinical suspicion is not low, immediate management. Send an immunoassay (anti-PF4/heparin ELISA). Confirm with a functional assay (serotonin-release assay or heparin-induced platelet activation) when the ELISA is positive or the clinic picture is compelling. Do not wait for the serotonin-release assay to stop heparin if the 4Ts score is intermediate or high.
Management is three simultaneous moves. Stop all heparin, including catheter flushes, heparin-coated lines, and LMWH. Start a non-heparin anticoagulant — argatroban (hepatically cleared; it raises the INR and complicates warfarin overlap), bivalirudin, or, in selected stable patients with adequate kidneys, fondaparinux or a direct oral anticoagulant. Do not start warfarin until platelets have substantially recovered; premature warfarin can cause venous limb gangrene through protein C depletion. Platelet transfusion is generally avoided in HIT unless there is life-threatening bleeding, because adding platelets to an activating antibody can worsen thrombosis.
UFH causes HIT more often than LMWH. Fondaparinux rarely causes HIT. Patients with recent heparin need a baseline platelet count and monitoring while exposed. A falling count on heparin after craniotomy is not “surgical consumption” by default if the timing and a new DVT fit HIT.
| 4Ts domain | Higher-probability pattern |
|---|---|
| Thrombocytopenia | >50% fall, nadir ≥20 × 10^9/L |
| Timing | Day 5–10, or ≤1 day if heparin in the prior month |
| Thrombosis | New VTE/arterial clot, skin necrosis, systemic heparin reaction |
| Other causes | No alternative explanation for the drop |
Exam traps
Do not delay IPC until “the hematoma is stable.” Do not claim a randomized trial proved that every post-craniotomy patient must start LMWH at a single clock time. Do not treat PE after ICH with a week of observation and no filter and no anticoagulation plan. Do not leave a retrievable filter in for life. Do not treat HIT with warfarin while the count is still 20 × 10^9/L, and do not “just give platelets” for HIT.
A nonambulatory patient is diagnosed with spontaneous ICH 2 hours ago. Blood pressure is now controlled. Which VTE prophylaxis action is indicated immediately?
On a post-craniotomy TBI patient, the surgeon asks when prophylactic LMWH may start. Which statement is most accurate for this examination?
Day 4 after ICH, duplex ultrasound shows a femoral DVT. The hematoma is still large, INR is normal, and the team judges therapeutic anticoagulation absolutely contraindicated today. What is the best next step regarding an IVC filter?
A patient 8 days after UFH prophylaxis has a platelet fall from 280 to 90 × 10^9/L and a new arm-vein thrombosis. The 4Ts score is high. What is the most appropriate immediate management?